- Home
- MMI vs XNCR Comparison
MMI vs XNCR Comparison
Compare MMI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- XNCR
- Stock Information
- Founded
- MMI 1971
- XNCR 1997
- Country
- MMI United States
- XNCR United States
- Employees
- MMI N/A
- XNCR N/A
- Industry
- MMI Real Estate
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- XNCR Health Care
- Exchange
- MMI Nasdaq
- XNCR Nasdaq
- Market Cap
- MMI 1.2B
- XNCR 579.3M
- IPO Year
- MMI 2013
- XNCR 2013
- Fundamental
- Price
- MMI $31.51
- XNCR $8.57
- Analyst Decision
- MMI Sell
- XNCR Buy
- Analyst Count
- MMI 1
- XNCR 7
- Target Price
- MMI $30.00
- XNCR $27.50
- AVG Volume (30 Days)
- MMI 169.4K
- XNCR 750.9K
- Earning Date
- MMI 08-06-2025
- XNCR 08-04-2025
- Dividend Yield
- MMI 1.57%
- XNCR N/A
- EPS Growth
- MMI N/A
- XNCR N/A
- EPS
- MMI N/A
- XNCR N/A
- Revenue
- MMI $711,994,000.00
- XNCR $127,228,000.00
- Revenue This Year
- MMI $11.69
- XNCR N/A
- Revenue Next Year
- MMI $24.07
- XNCR $28.84
- P/E Ratio
- MMI N/A
- XNCR N/A
- Revenue Growth
- MMI 14.79
- XNCR N/A
- 52 Week Low
- MMI $27.61
- XNCR $7.16
- 52 Week High
- MMI $42.80
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- MMI 55.27
- XNCR 50.54
- Support Level
- MMI $30.19
- XNCR $7.93
- Resistance Level
- MMI $32.50
- XNCR $8.57
- Average True Range (ATR)
- MMI 0.85
- XNCR 0.49
- MACD
- MMI 0.08
- XNCR 0.01
- Stochastic Oscillator
- MMI 68.06
- XNCR 79.57
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.